Biogen Data at ECTRIMS 2022 Highlight Innovation in Digital Health
Focused on Advancing Treatment and Personalized Care of People
Living with MS
Biogen Inc. (Nasdaq: BIIB) announced new data on multiple
sclerosis (MS) disease measurement and advanced analytics being
presented at the 38th Congress of the European Committee for
Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting
October 26-28, 2022. These data highlight Biogen’s multi-pronged
approach to pursue MS-related digital health research aimed at
supporting the development of new treatments, individualizing care,
and advancing the understanding of disease heterogeneity.
“Biogen is working to realize a future where multi-dimensional
data are leveraged to better characterize and monitor MS disease
progression and to predict therapy response at an individual
level,” said Shibeshih Belachew, M.D., Ph.D., Head of Science,
Biogen Digital Health. “This year’s ECTRIMS presentations represent
our ongoing digital health research and highlight progress in
developing advanced measurement methods that aim to enhance drug
development and personalized care for better patient outcomes.”
Developing Digital Tools for More Precise MS Disease
Measurement Multiple presentations at ECTRIMS highlight
the potential for technology to provide new opportunities in
disease measurement through digital health technology tools. A
poster investigating the relationship between novel measures from a
technology-enabled nine-hole peg test called the Manual Dexterity
Test (MDT) included 3,525 patients and 44,394 MDT observations.
Results suggest that overall MDT time is a reliable measure that
correlates with changes in disability progression and quality of
life in MS patients and that a new metric of MDT speed yields
superior predictive models of disease progression relative to
overall MDT time.
Two additional posters analyzed interim data from the DigiToms
study [NCT04756700] evaluating a smartphone-based Cognitive
Processing Speed (CPS) Test from Konectom™, a mobile application
that is intended to be used as a self-assessment tool to
objectively quantify motor and cognitive functions. Data
demonstrate that CPS score and response time features are sensitive
to cognitive impairment and show discriminative validity between
people with MS and healthy participants. A second poster outlines
differences in three outcome measures of the CPS test when
performed with a fixed reference key versus a dynamic reference
key, an important element of test design. MDT and Konectom are
currently only used in limited research settings.
Applying Machine Learning, Artificial Intelligence and
Radiomics to Generate MS Disease Progression Insights
Three presentations at ECTRIMS feature the most recent research
from Biogen’s collaboration with TheraPanacea, which aims to
develop computer-aided diagnosis software solutions to accelerate
drug development and improve patient care using machine learning
(ML), artificial intelligence (AI) and radiomics. One poster
demonstrates that machine learning and radiomics may extract more
information about the heterogeneity observed in MS lesions than is
currently possible from a visual read. Nearly 2,400 MRI scans from
the ADVANCE and ASCEND Phase 3 clinical trials were retrospectively
analyzed, and clusters of acute MS lesions were identified with
specific spatial, geometric, and textural patterns. Two additional
posters focus on advancing technical capabilities of conventional
MRI by using novel ML-AI-based algorithms for MS lesion
segmentation.
Advancing Precision Medicine Models Toward Predicting
Individual Treatment Response The ability to more
precisely predict how individuals will respond to treatment is
needed to advance personalized care and improve patient outcomes.
One poster at ECTRIMS highlights analyses using real-world data
from 1,600 patients in the MS PATHS (Partners Advancing Technology
and Health Solutions) network. Researchers were able to replicate
findings from published two-stage precision medicine models that
were applied to clinical trial data, providing proof of concept for
this analytical methodology using real-world data. The use of
two-stage precision medicine models may eventually offer a pathway
for predicting and choosing specific treatments in actual practice
based on an individual’s own presentation of disease.
Title and Times of Biogen Digital Health Data
Presentations at ECTRIMS:
- Unsupervised Clustering of Acute
Multiple Sclerosis Lesions across Spatial, Geometric and Textural
Domains – EP0978 – October 26, 8 a.m. CET / 2 a.m. ET
- Moving Beyond the Number of Correct
Responses as an Outcome Measure in Symbol-digit Substitution
Testing using Konectom Smartphone-based Cognitive Processing Speed
Test – EP1159– October 26, 8 a.m. CET / 2 a.m. ET
- Glial Fibrillary Acidic Protein and
Multiple Sclerosis Progression Independent of Acute Inflammation –
EP1019 – October 26, 8 a.m. CET / 2 a.m. ET
- Machine Learning Parcellation of
Multiple Sclerosis Lesions into Texturally Consistent Super-Voxels
for Lesion Classification – EP1008 – October 26, 8 a.m. CET / 2
a.m. ET
- Longitudinal Association of
Intra-Task Measures Derived from a Technology-Enabled 9-Hole Peg
Test with Disease Progression and Quality of Life in Multiple
Sclerosis – P093 – October 26, 8 a.m. CET / 2 a.m. ET
- Performance Differences Observed
with Fixed Versus Dynamic Reference Keys within Konectom
Smartphone-based Cognitive Processing Speed Test – P042 – October
26, 8 a.m. CET / 2 a.m. ET
- Proof of Concept for 2-stage Models
of Heterogeneous Treatment Effects Derived from the Real-World MS
PATHS Research Network – P372 – October 26, 8 a.m. CET / 2
a.m. ET
- A Novel Deep Learning Algorithm for
Multi-Modal Multiple Sclerosis Lesion Segmentation – P227 - October
26, 8 a.m. CET / 2 a.m. ET
- Motion Capture of the Manual
Dexterity Test to Categorize Hand Function in Multiple Sclerosis –
P499 – October 26, 8 a.m. CET / 2 a.m. ET
- Assessment of Candidate MRI
Biomarkers of Ongoing MS Disease in the Absence of Acute
Inflammation – P618 – October 26, 8 a.m. CET / 2 a.m. ET
About Biogen Digital HealthBiogen Digital
Health is a global unit of Biogen dedicated to pioneering
personalized and digital medicine in neuroscience. We aspire to
transform patients’ lives by making personalized and digital
medicine in neuroscience a reality. Powered by data-science and
digital technologies, we drive solutions to advance research,
clinical care, and patient empowerment. We believe that now, more
than ever, biology and technology should go hand-in-hand to better
meet patient needs, while enabling a shift towards more
prevention-focused, affordable, and equitable care.
About BiogenAs pioneers in neuroscience, Biogen
discovers, develops, and delivers worldwide innovative therapies
for people living with serious neurological diseases as well as
related therapeutic adjacencies. One of the world’s first global
biotechnology companies, Biogen was founded in 1978 by Charles
Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize
winners Walter Gilbert and Phillip Sharp. Today, Biogen has a
leading portfolio of medicines to treat multiple sclerosis, has
introduced the first approved treatment for spinal muscular
atrophy, and developed the first and only approved treatment to
address a defining pathology of Alzheimer’s disease. Biogen is also
commercializing biosimilars and focusing on advancing one of the
industry’s most diversified pipelines in neuroscience that will
transform the standard of care for patients in several areas of
high unmet need.
In 2020, Biogen launched a bold 20-year, $250 million initiative
to address the deeply interrelated issues of climate, health, and
equity. Healthy Climate, Healthy Lives™ aims to eliminate fossil
fuels across the company’s operations, build collaborations with
renowned institutions to advance the science to improve human
health outcomes, and support underserved communities.
We routinely post information that may be important to investors
on our website at www.biogen.com. Follow us on social
media - Twitter, LinkedIn, Facebook, YouTube.
Biogen Safe HarborThis news release contains
forward-looking statements, including statements made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995, relating to the potential benefits, safety and
efficacy of digital tools; the results of certain real-world data;
clinical trials and data readouts and presentations; the
identification and treatment of MS; our research and development
program for the treatment of MS; and the potential of our
commercial business, including Biogen Digital Health and digital
tools. These forward-looking statements may be identified by words
such as “aim,” “anticipate,” “believe,” “could,” “estimate,”
“expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,”
“potential,” “will,” “would” and other words and terms of similar
meaning. Drug development and commercialization involve a high
degree of risk, and only a small number of research and development
programs result in commercialization of a product. You should not
place undue reliance on these statements or the scientific data
presented.
These statements involve risks and uncertainties that could
cause actual results to differ materially from those reflected in
such statements, including without limitation the occurrence of
adverse safety events and/or unexpected concerns that may arise
from additional data or analysis; risks of unexpected costs or
delays; failure to protect and enforce our data, intellectual
property and other proprietary rights and uncertainties relating to
intellectual property claims and challenges; product liability
claims; third party collaboration risks; and the direct and
indirect impacts of the ongoing COVID-19 pandemic on our business,
results of operations and financial condition. The foregoing sets
forth many, but not all, of the factors that could cause actual
results to differ from our expectations in any forward-looking
statement. Investors should consider this cautionary statement as
well as the risk factors identified in our most recent annual or
quarterly report and in other reports we have filed with the U.S.
Securities and Exchange Commission. These statements are based on
our current beliefs and expectations and speak only as of the date
of this news release. We do not undertake any obligation to
publicly update any forward-looking statements, whether as a result
of new information, future developments or otherwise.
MEDIA CONTACT:Allison Parks+ 1 248 229
4461public.affairs@biogen.com |
INVESTOR CONTACT:Mike Hencke+1 781 464 2442IR@biogen.com |
Biogen (TG:IDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biogen (TG:IDP)
Historical Stock Chart
From Jul 2023 to Jul 2024